Clinical Trials Browser

Phase 4 × Cardiotoxicity × Trastuzumab × Clear all

NCT04928261 2026-01-22

Evaluating 6-months of HER2-targeted Therapy in Patients With HER2 Positive Early-stage Breast Cancer That Achieve a Pathological Complete Response to Neoadjuvant Systemic Therapy

Phase 4 Active not recruiting

Breast Neoplasms, Cardiotoxicity